Mdxhealth Sa's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Mdxhealth Sa (MDXH) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Mdxhealth Sa vs Its Competitors
- TTM: Trailing 12-month revenue of 108M vs 36,563M combined for its competitors (0.3% combined share).
- Trending: Latest-quarter revenue run-rate is accelerating (+300.0% annualized vs trailing 12 months), vs decelerating (-2.1%) for its tracked peer group.
- Profitability: Its -31.1% net margin compares with 2.0% for the peer group.
- Scale: Mdxhealth Sa ranks #38 of 46 companies by market capitalization in the Medical Laboratories industry, holding 0.0% of industry market cap.
- Peer revenue share: Mdxhealth Sa accounted for 1.2% of combined revenue among its tracked peer group.
- Peer differentiation: Revenue per employee of $0.53M compares with $0.24M for the peer group (2.2x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
MDXH Sales vs. its Competitors, Q4 2025
With a net margin of -31.07 %, Mdxhealth Sa reported lower profitability than its competitors (2.04 %).
Mdxhealth Sa generated 1.19 % of the combined sales of its peer group.
API endpoints for this dataset
Mdxhealth Sa vs. its Competitors, Q4 2025
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in Mdxhealth Sa reports; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Mdxhealth Sa and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Mdxhealth Sa | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| High-Confidence Competitors (8) | $12,345M | +12.3% · Accelerating |
| Similar-Size Competitors (8) | $12,345M | +12.3% · Accelerating |
| Similar Growth & Profitability (7) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Mdxhealth Sa's competitor groups requires a Commercial License.
Mdxhealth Sa's Competitor Quality Breadth
Group definitions: see Methodology: Performance Group Definitions.
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Mdxhealth Sa | No | Yes | Yes | No |
| Competitors combined (18) | ||||
| High-Confidence Competitors (9) | ||||
| Similar-Size Competitors (8) | ||||
| Similar Growth & Profitability (8) | 12.50 % (1 of 8) | 100.00 % (8 of 8) | 75.00 % (6 of 8) | 12.50 % (1 of 8) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
MDXH Stock Performance relative to its Competitors
MDXH Stock Performance relative to High-Confidence Competitors
MDXH Stock Performance relative to Similar-Size Competitors
MDXH Stock Performance relative to Similar Growth & Profitability Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Caredx Inc | 282.9% | Outperformed |
| 2 | Exact Sciences Corporation | 282.9% | Outperformed |
| 3 | Personalis Inc | 282.9% | Outperformed |
| 4 | Natera Inc | 282.9% | Outperformed |
| 5 | Guardant Health Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Mdxhealth Sa's best-performing competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Mdxhealth Sa's Comment on Competition and Industry Peers
Publicly Traded Peers of Mdxhealth Sa
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
 Mdxhealth Sa |
7.84 | 107.88 |
 Natera Inc |
44,512.49 | 2,707.08 |
 Labcorp Holdings Inc |
29,912.11 | 14,594.50 |
 Quest Diagnostics Inc |
28,630.56 | 11,841.00 |
 Guardant Health Inc |
20,045.64 | 1,183.11 |
 Exact Sciences Corporation |
19,599.02 | 3,245.31 |
| SUBTOTAL | 153,469.27 | 36,685.31 |
Sign in to see all competitors of Mdxhealth Sa.
Sources: see Methodology: Peer & Competitor Identification, Sourcing.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Mdxhealth Sa versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Mdxhealth Sa's Competitors Named by the Company
Competitive relationships identified from Mdxhealth Sa reports and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Volitionrx Limited | Company report | 85% |
| Manhattan Scientifics Inc | Company report | 85% |
| Veracyte | Company report | 85% |
| Beckman Coulter | Company report | 85% |
| Labcorp | Company report | 85% |
| OPKO Health | Company report | 85% |
| Bio-Techne | Company report | 85% |
| Michigan Medicine | Company report | 85% |
| ExosomeDx | Company report | 85% |
| Exact Sciences | Company report | 85% |
| Myriad Genetics | Company report | 85% |
| Hologic | Company report | 85% |
| Natera Inc | Company report | 85% |
| Sera Prognostics Inc | Company report | 85% |
| Invitae Corporation | Company report | 85% |
| Quest Diagnostics Inc | Company report | 85% |
| Exagen Inc | Company report | 85% |
| Personalis Inc | Company report | 85% |
| Guardant Health Inc | Company report | 85% |
| Centogene N v | Company report | 85% |
Company report basis, confidence, active dates and source counts for Mdxhealth Sa's named competitors require a Commercial License.
Methodology: see Methodology: Peer & Competitor Identification, Sourcing.
Mdxhealth Sa's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Natera Inc | Reportable 100.00 % |
| Labcorp Holdings Inc | Diagnostics 77.40 % |
| Quest Diagnostics Inc | Diagnostic Information Services Business 98.00 % |
| Guardant Health Inc | Reportable 100.00 % |
| Caredx Inc | Reportable 100.00 % |
Source: operating segment revenue as reported in each company's reports (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Mdxhealth Sa's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Mdxhealth Sa | 8 | 534,035 | -165,936 |
| Natera Inc | 44,512 | 440,892 | -31,327 |
| Labcorp Holdings Inc | 29,912 | 208,493 | 14,354 |
| Quest Diagnostics Inc | 28,631 | 207,737 | 20,456 |
| Guardant Health Inc | 20,046 | 472,109 | -180,940 |
| Exact Sciences Corporation | 19,599 | 450,738 | -28,882 |
| PEERS TOTAL | 153,461 | 241,391 | 6,622 |
Mdxhealth Sa's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent report. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Natera Inc | United States 98.02 % |
| Guardant Health Inc | United States 95.67 % |
| Exact Sciences Corporation | United States 93.11 % |
| Caredx Inc | United States 99.60 % |
| Opko Health Inc | IE 27.07 % |
Source: revenue geography as reported in each company's reports (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Mdxhealth Sa's Position in Industry Market Structure
Market-capitalization share and concentration across all 41 companies in Mdxhealth Sa's industry classification, broader than the peer set above. Market cap in millions of $.Mdxhealth Sa ranks #38 of 41 companies by market capitalization in its industry, holding 0.00 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 805, indicating a unconcentrated market structure (see Methodology: Market Structure & Concentration).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Iqvia Holdings Inc | 45,477 | 12.91 % |
| 2 | Natera Inc | 44,512 | 12.63 % |
| 3 | Ge Healthcare Technologies Inc | 37,401 | 10.62 % |
| 4 | Labcorp Holdings Inc | 30,059 | 8.53 % |
| 5 | Quest Diagnostics Inc | 1,234 | 5.2% |
| 6 | Koninklijke Philips Nv | 1,234 | 5.2% |
| 7 | Incyte Corporation | 1,234 | 5.2% |
| 8 | Guardant Health Inc | 1,234 | 5.2% |
| 9 | Medpace Holdings Inc | 1,234 | 5.2% |
| 10 | Charles River Laboratories International inc | 1,234 | 5.2% |
| 38 | Mdxhealth Sa | 4 | 0.00 % |
Market cap and industry share for the rest of Mdxhealth Sa's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-11-06.
Mdxhealth Sa's Same-Size Peers & Stock Performance
Peers chosen by closeness in market-cap rank within the same industry classification (not the named-competitor list above). Trailing 12-month total return, 3-month price momentum, beta and Sharpe ratio vs the broad U.S. market.| Rank | Company | Market Cap | TTM Return |
|---|---|---|---|
| 33 | Biodesix Inc | 88 | 37.04 % |
| 34 | Nano X Imaging Ltd | 16 | -92.62 % |
| 35 | Bioaffinity Technologies Inc | 14 | 27.42 % |
| 36 | American Shared Hospital Services | 1,234 | 12.3% |
| 37 | Aclarion Inc | 1,234 | 12.3% |
| 38 | Mdxhealth Sa | 4 | -96.68 % |
| 39 | Bionexus Gene Lab Corp | 1,234 | 12.3% |
| 40 | Ispecimen inc | 1,234 | 12.3% |
| 41 | First Choice Healthcare Solutions Inc | 1,234 | 12.3% |
Market cap, return, momentum, beta and Sharpe ratio for the rest of Mdxhealth Sa's same-size peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation); returns and risk metrics as of 2026-11-06. Beta and Sharpe ratio are versus the broad U.S. equity market, not this industry.
Mdxhealth Sa's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Medical Laboratories industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (77 companies). See the full Medical Laboratories industry profitability benchmarks.| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | 64.55 % | 33.04 % (avg) | +31.5 pp |
| Operating Margin | -13.36 % | industry median | -7.0 pp |
| EBITDA Margin | -24.26 % | -4.66 % (avg) | -19.6 pp |
| Capital Intensity (Capex / Revenue) | 1.07 % | 7.45 % (avg) | -6.4 pp |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
Mdxhealth Sa's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in company reports.| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue Growth | 89.43 % | 28.29 % | 19.80 % |
| Operating Margin | -38.93 % | -27.45 % | -13.36 % |
| Return on Invested Capital | -23.39 % | -83.29 % | -23.52 % |
| P/E | - | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Mdxhealth Sa's Strategic Group Map
Mdxhealth Sa is shown in red; its closest peers by combined growth, margin and ROIC are labeled. See Methodology: Strategic Group Map for how this chart is built.
Mdxhealth Sa's trailing-12-month revenue growth of 19.8% and operating margin of -13.4% compares with an average of 20.5% growth and -11.9% margin across its 8 closest peers by combined growth, margin and ROIC -- Mdxhealth Sa sits below that peer average on growth and below it on margin.
Source: CSIMarket API, trailing 12 months. Extreme outlier values (from near-zero-revenue companies) are excluded from the plotted cloud but never from the highlighted company or its labeled peers.
Mdxhealth Sa's BCG Growth-Share Matrix
See Methodology: BCG Growth-Share Matrix for how relative share and growth are calculated and thresholded.
Mdxhealth Sa falls in the Dog quadrant: relative market share of 0.00x vs its largest competitor, in an industry growing revenue 5.6% (median, trailing 12 months).
Source: CSIMarket API (market-cap share and industry revenue growth). The 10% growth and 1.0x share lines are standard textbook thresholds, not derived from this industry's own distribution.
Mdxhealth Sa's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | High | Industry HHI of 805 (see Industry Market Structure & Concentration above) |
| Barriers to Entry | Lower than typical for the industry | Capital intensity (capex / revenue) of 1.07 % vs industry average 7.45 % (see Profitability & Cost Structure above) |
Note: see Methodology: Porter's Five Forces. Supplier power and buyer power are covered on Mdxhealth Sa's dedicated Suppliers and Customers pages, not here.
Mdxhealth Sa's Industry Attractiveness & Competitive Strength
See Methodology: GE/McKinsey Matrix for how the two axes are built.
Mdxhealth Sa falls in the Low attractiveness / Medium strength cell: Harvest.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Mdxhealth Sa's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Latest-quarter revenue run-rate is accelerating (+300.0% annualized vs trailing 12 months).
Weaknesses
- Operating margin 7.0 points below the industry median.
- Underperforming the U.S.A. 500 over the trailing 12 months.
- Low relative market share vs the industry leader (0.00x).
Opportunities
No rule matched.
Threats
- Tracked peer group's revenue run-rate is broadly decelerating (-2.1% annualized).
Methodology: see Methodology: SWOT Analysis.
Mdxhealth Sa's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Mdxhealth Sa | 0.59 | 1.08 | - |
| Natera Inc | - | 3.14 | 0.05 |
| Labcorp Holdings Inc | 0.18 | 1.57 | 0.68 |
| Quest Diagnostics Inc | 0.28 | 1.35 | 0.74 |
| Guardant Health Inc | 2.56 | 4.29 | - |
| Exact Sciences Corporation | 1.22 | 2.68 | 0.95 |
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Mdxhealth Sa's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Mdxhealth Sa | Q4 2025 | +19.8 % | - |
| Natera Inc | Q2 2026 | +37.7 % | - |
| Labcorp Holdings Inc | Q3 2026 | +6.9 % | +0.5 % |
| Quest Diagnostics Inc | Q3 2026 | +10.0 % | +20.5 % |
| Guardant Health Inc | Q2 2026 | +44.3 % | - |
| Exact Sciences Corporation | Q4 2025 | +23.1 % | - |
| PEERS TOTAL | +12.5 % | - |
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Mdxhealth Sa's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Mdxhealth Sa | Q4 2025 | +9.6 % | -2.6 % |
| Natera Inc | Q2 2026 | -99.3 % | +144.9 % |
| Labcorp Holdings Inc | Q3 2026 | +6.4 % | +56.1 % |
| Quest Diagnostics Inc | Q3 2026 | +10.1 % | +15.3 % |
| Guardant Health Inc | Q2 2026 | +42.8 % | +108.2 % |
| Exact Sciences Corporation | Q4 2025 | +19.5 % | - |
Mdxhealth Sa's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Mdxhealth Sa | - | - | - |
| Natera Inc | - | - | - |
| Labcorp Holdings Inc | 5.36% | 6.07% | 11.55% |
| Quest Diagnostics Inc | 6.96% | 8.01% | 15.22% |
| Guardant Health Inc | - | - | - |
| Exact Sciences Corporation | - | - | - |
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Mdxhealth Sa's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Mdxhealth Sa | - | 0.07 |
| Natera Inc | - | 16.44 |
| Labcorp Holdings Inc | 30.10 | 2.05 |
| Quest Diagnostics Inc | 25.74 | 2.42 |
| Guardant Health Inc | - | 16.94 |
| Exact Sciences Corporation | - | 6.04 |
| PEERS AVERAGE | 158.22 | 4.18 |
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.